Amprenavir

DB00701ApprovedWithdrawnSmall moleculeProtease Inhibitors

Amprenavir is a protease inhibitor used to treat HIV infection.

Chemical structure of Amprenavir
Mechanism
Curator reviewed
Primary indication
For the treatment of HIV-1 infection in combination with other antiretroviral agents.Curator reviewed
Formula / weight
C25H35N3O6S · 505.627 g/mol (avg)
First approval
Canada, 2004 · United States, 1999
Code names
141 W 94 · KVX-478 · VX-478

Resolves to

Compound
UNII5S0W860XNRCAS161814-49-9ChEMBLCHEMBL116ChEBI40050PubChem65016KEGGD00894
Clinical / RWD
RxNorm228656ATCJ05AE05PharmGKBPA448422
Structure
InChIKeyYMARZQAQMVYCKC-OEMFJLHTSA-NSMILESCC(C)CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)C1=CC=C(N)C=C1
Targets
Q72874polP03366gag-pol
Transporters
P08183ABCB1P33527ABCC1Q9Y6L6SLCO1B1

What you can answer from here — as of September 23, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action
Listed above
3TransportersSubstrate / inhibitor direction, not just membership
Listed above
1,186Drug interactionsStructured to mechanism, not free text
Sign in
14Clinical trialsPhase, status and sponsor resolved per trial
Sign in
3ContraindicationsEach with its own population and attribute set
Sign in
15Marketed productsAcross 5 countries and 3 labellers
Sign in
1ATC codeIncluding every combination product, plus 41 drug categories
Sign in
21+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Amprenavir, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In